HC Wainwright Has Pessimistic Opinion of HRMY Q3 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for Harmony Biosciences in a research note issued on Tuesday, October 27th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn $0.88 per share for the quarter, down from their prior forecast of $1.00. HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $3.79 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q4 2026 earnings at $0.79 EPS.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $1.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.96 by $0.32. The company had revenue of $261.28 million during the quarter, compared to analysts’ expectations of $250.77 million. The company’s revenue was up 30.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.92 earnings per share.

HRMY has been the topic of a number of other reports. Needham & Company LLC restated a “buy” rating and issued a $50.00 price target on shares of Harmony Biosciences in a report on Monday, October 19th. Wolfe Research assumed coverage on shares of Harmony Biosciences in a research note on Wednesday, August 26th. They issued an “outperform” rating and a $60.00 target price for the company. UBS Group reaffirmed a “neutral” rating and issued a $37.00 price target on shares of Harmony Biosciences in a report on Wednesday, August 5th. Weiss Ratings raised Harmony Biosciences from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, October 12th. Finally, Zacks Research upgraded Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Harmony Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $48.20.

Harmony Biosciences Stock Up 3.0%

Shares of HRMY stock opened at $37.95 on Wednesday. Harmony Biosciences has a 1-year low of $25.90 and a 1-year high of $43.49. The stock’s 50-day moving average is $39.78 and its 200 day moving average is $34.72.

Insider Activity at Harmony Biosciences

In related news, insider Kumar Budur sold 35,852 shares of Harmony Biosciences stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $43.05, for a total value of $1,543,428.60. Following the completion of the sale, the insider directly owned 13,115 shares in the company, valued at $564,600.75. This trade represents a 73.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders have sold 72,406 shares of company stock valued at $3,108,520. Company insiders own 11.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in shares of Harmony Biosciences during the second quarter worth $258,583,000. Dimensional Fund Advisors LP lifted its position in Harmony Biosciences by 13.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,076,510 shares of the company’s stock worth $58,157,000 after acquiring an additional 245,784 shares during the period. Renaissance Technologies LLC lifted its position in Harmony Biosciences by 0.6% during the 1st quarter. Renaissance Technologies LLC now owns 1,077,371 shares of the company’s stock worth $30,177,000 after acquiring an additional 6,900 shares during the period. venBio Partners LLC purchased a new stake in Harmony Biosciences during the 2nd quarter valued at about $17,192,584. Finally, Pacer Advisors Inc. grew its stake in Harmony Biosciences by 9.7% during the 1st quarter. Pacer Advisors Inc. now owns 318,527 shares of the company’s stock valued at $8,922,000 after purchasing an additional 28,174 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial-stage biopharmaceutical company focused on developing and providing therapies for patients with rare neurological disorders. The company’s activities center on conditions involving sleep-wake regulation and other central nervous system disorders where treatment options may be limited.

Harmony’s principal product is WAKIX (pitolisant), an oral, non-scheduled treatment that acts as a histamine-3 receptor antagonist/inverse agonist. In the United States, WAKIX is approved for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy and for excessive daytime sleepiness in pediatric patients aged 6 and older with narcolepsy.